https://pharmoniq.com/news/fda-warning-letters-hangover-supplement-companies-illegal-claims PharmoniQ en 2026-10-04T14:10:49.115Z FDA Targets Hangover Supplement Makers in Marketing Claims Crackdown FDA, warning-letters, hangover-supplements, marketing-claims, enforcement https://pharmoniq.com/news/novo-nordisk-korro-bio-rna-editing-deal-530-million PharmoniQ en 2026-10-04T08:47:02.601Z Novo Nordisk Commits $530M to RNA Editing in Korro Bio Deal RNA editing, Novo Nordisk, Korro Bio, gene therapy, precision medicine https://pharmoniq.com/news/fda-warning-letter-american-pharma-manufacturing-gmp-violations PharmoniQ en 2026-10-03T14:10:48.994Z FDA Issues Warning Letter Over Serious Manufacturing Violations FDA, CGMP violations, warning letter, pharmaceutical manufacturing, regulatory compliance https://pharmoniq.com/news/fda-approves-first-once-weekly-insulin-type-2-diabetes PharmoniQ en 2026-10-03T08:47:02.690Z FDA Approves First Once-Weekly Insulin for Type 2 Diabetes FDA approval, insulin therapy, Type 2 Diabetes, medication adherence, once-weekly dosing